Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab in Stage IIb/c Melanoma
NCT07349303Phase 2Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Jan 2026
- Primary completion
- May 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, sponsored by Region Västra Götaland. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07349303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349303.